Biotech Collaborations Market Report 2025

The biotech collaborations market size has grown rapidly in recent years. It will grow from $84.59 billion in 2024 to $94.35 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period was driven by increasing demand for novel therapeutics, rising research and development expenditure, growing prevalence of chronic diseases, expanding regulatory complexities, and higher adoption of advanced biotechnologies.

The biotech collaborations market size is expected to see rapid growth in the next few years. It will grow to $144.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth during the forecast period is fueled by growing investments in biotech startups, rising demand for sustainable and green bioprocesses, increased focus on personalized medicine, expanding adoption of gene and cell therapies, and a growing need for cost optimization. The primary trends in the forecast period include development of next-generation biologics, integration of omics data, incorporation of digital health technologies, innovation in drug delivery systems, and advancement of sustainable bioprocesses.

The growing demand for personalized medicine is expected to drive the expansion of the biotech collaborations market in the coming years. Personalized medicine tailors treatment and prevention strategies to an individual’s unique genetic profile, lifestyle, and environment. This surge in personalized medicine adoption is largely due to advancements in genomics, which allow for the precise identification of genetic variations and the development of tailored treatments. Biotech collaborations play a crucial role in this progress by combining expertise and innovative technologies, accelerating the development of targeted therapies for individual patients. These collaborations reduce research timelines and improve the success rates of new treatments, enhancing both efficacy and patient outcomes. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant rise from the 12 approved in 2022. As a result, the demand for personalized medicine is driving growth in the biotech collaborations market.

Companies in the biotech collaborations market are focusing on developing innovative solutions, such as artificial intelligence (AI)-driven drug discovery platforms, to accelerate the identification of new therapeutics and improve research and development efficiency. AI-driven drug discovery platforms leverage advanced algorithms and machine learning to analyze biological data, predict drug-target interactions, and streamline the development of new treatments. For instance, in January 2025, Iktos S.A.S., a France-based biotechnology company, partnered with Cube Biotech GmbH, a Germany-based biotech company, to develop novel small molecule agonists targeting the amylin receptor, a promising therapeutic target for cardiometabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatotic hepatitis (MASH). This collaboration combines Iktos’ generative AI-driven drug discovery platform with Cube Biotech’s expertise in membrane protein technology and protein stabilization methods. The partnership aims to accelerate drug discovery timelines, enhance success rates, and improve targeting of challenging membrane proteins, offering potential therapies that could be more efficient and cost-effective than current treatments, such as GLP-1 receptor agonists.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition strengthens Pfizer's oncology portfolio, expands its pipeline of targeted cancer therapies, and positions the company for long-term growth in the oncology space. Seagen, a biopharmaceutical company based in the U.S., has established strategic collaborations to advance its oncology pipeline.

Major players in the biotech collaborations market are Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., C.H. Boehringer Sohn AG & Co. KG, CSL Limited., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, and Biogen Inc.

North America was the largest region in the biotech collaborations market in 2024. The regions covered in biotech collaborations report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biotech collaborations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Biotech collaborations refer to strategic partnerships between biotechnology companies, research institutions, or other organizations aimed at jointly developing, researching, or commercializing biotechnological products and innovations. These collaborations facilitate the sharing of expertise, resources, and technologies to accelerate innovation, reduce risks, and bring advanced biotech solutions to market more efficiently.

The primary types of biotech collaborations are research and development collaborations, licensing agreements, joint ventures, mergers or acquisitions, and others. Research and development collaborations involve strategic partnerships between two or more organizations to jointly conduct scientific research and develop new products, technologies, or processes. These collaborations support applications such as drug discovery, clinical research, diagnostics, therapeutics, and others, and serve end users including pharmaceutical companies, biotechnology firms, academic and research institutes, and others.

The biotech collaborations market research report is one of a series of new reports that provides biotech collaborations market statistics, including biotech collaborations industry global market size, regional shares, competitors with a biotech collaborations market share, detailed biotech collaborations market segments, market trends and opportunities, and any further data you may need to thrive in the biotech collaborations industry. This biotech collaborations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biotech collaborations market includes revenues earned by entities through clinical trial services, licensing and technology transfer, manufacturing and contract development, regulatory and consulting services, and bioinformatics and data analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.